Novo Nordisk launched an oral form of semaglutide branded as Wegovy and started U.S. distribution with pricing tiers intended to expand access: as low as $25 per month for insured patients under certain plans and $149 per month cash price for the starting dose. Phase 3 data cited by the company showed the top oral dose produced about 16.6% mean weight loss at 64 weeks in trial populations, close to results from weekly injectables. Novo highlighted the pill as a step to broaden uptake but noted dose and pharmacokinetic differences versus injectables.